Clinical trials: Graft-versus-Host Disease
Acute Graft-versus-Host Disease
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
The purpose of this study is to compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of patients with newly diagnosed acute GvHD (Grades…
- Trial name
- NCT00282503
- Testing
- Methoxsalen+ECP, Methylprednisolone, Ecp
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 19 people
- Sponsor
- Mallinckrodt
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- AXemplify-357 (NCT06585774)
- Testing
- INCA034176, Corticosteroids
- Where
- 131 sites in United States, Australia and 11 more
- Volunteers
- 240 people
- Sponsor
- Incyte Corporation
Acute-graft-versus-host Disease
ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Acute GVHD following allogeneic HCT is an immune-triggered process, leading to profound immune dysregulation and organ dysfunction.
- Trial name
- NCT04883918
- Testing
- ASC930
- Volunteers
- 60 people
- Sponsor
- ASC Therapeutics
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Steroid-refractory Acute Graft-versus-host Disease
A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment
It is a phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of VUM02 Injection in patients with acute graft-versus-host disease (aGvHD) who have failed systemic steroid therapy.
- Trial name
- ESTEVS-I/II (NCT06677255)
- Testing
- VUM02 Injection (UC-MSCs)+BAT, The control group with Best Available Therapy (BAT)
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Wuhan Optics Valley Vcanbiopharma Co., Ltd.
Acute Graft Versus Host Disease
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
The study was an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days…
- Trial name
- NCT03491215
- Testing
- Ruxolitinib
- Where
- 19 sites in Belgium, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft-versus-host-disease
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
The purpose of this study is to evaluate efficacy of SCM-CGH in participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial…
- Trial name
- NCT04189432
- Testing
- SCM-CGH
- Where
- 11 sites in South Korea
- Volunteers
- 84 people
- Sponsor
- SCM Lifescience Co., LTD.
Allogeneic Hematopoietic Stem Cell Transplantation
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants…
- Trial name
- NCT02728895
- Testing
- Vedolizumab
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Takeda
GVHD,Acute
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
The objective of this clinical study is to demonstrate safety and feasibility of single-dose infusion of Ossium MSCs product (OSSM-001) to treat steroid refractory acute GVHD (SR-aGVHD).
- Trial name
- NCT05443464
- Testing
- OSSM-001
- Sponsor
- Ossium Health, Inc.
Pain, Constipation
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
The primary research objective is to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation as measured by the Bowel Function Index (BFI) compared to subjects taking OxyPR tablets alone with cancer…
- Trial name
- NCT01438567
- Testing
- oxycodone/naloxone prolonged release (OXN PR) tablets, oxycodone prolonged release (OxyPR) tablets
- Where
- United Kingdom
- Volunteers
- 270 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Mycoses
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease
This trial is in high risk patients to determine the safety, tolerance and efficacy of posaconazole (POZ) vs. fluconazole in the prophylaxis against development of invasive fungal infections (IFI).
- Trial name
- NCT00034645
- Testing
- Posaconazole oral suspension
- Volunteers
- 600 people
- Sponsor
- Merck Sharp & Dohme LLC
Steroid-refractory Acute Graft Versus Host Disease
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).
- Trial name
- NCT06462469
- Testing
- Ruxolitinib
- Where
- 9 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Low Back Pain
Limiting Trunk Flexion as a Self-treatment for Low Back Pain
The purpose of the proposed study is to test the effect of an intervention technique that reduces trunk flexion upon rising, on the outcome measures of self-reported back pain and functional impairment in individuals with chronic…
- Trial name
- RST (NCT01830751)
- Testing
- Restrained Sitting Treatment
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Liberty Mutual Research Institute for Safety
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Myelodysplastic Syndromes, Leukemia Myeloid Acute
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless of whether they are highly…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leuklemia, Lymphocytic, Chronic
- Trial name
- GAH (NCT02164071)
- Testing
- Geriatric Assessment of Health Status Scale administration
- Where
- 22 sites in Spain
- Volunteers
- 363 people
- Sponsor
- Celgene
Cancer, Graft-Versus-Host Disease
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease
A clinical trial to assess safety and two regimens of (MEDI-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute Graft-versus-Host Disease.
- Trial name
- NCT00806728
- Testing
- MEDI-507
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- MedImmune LLC
Low Back Pain
Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain
To evaluate superiority of HDC in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.
- Trial name
- 144 (NCT01049373)
- Testing
- HDC
- Where
- Germany
- Volunteers
- 221 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Steroid Refractory Graft Versus Host Disease
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
- Trial name
- NCT07576699
- Testing
- CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Chronic Graft-versus-host-disease
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
- Trial name
- NCT06388564
- Testing
- Axatilimab, Ruxolitinib, Corticosteroids
- Where
- 68 sites in United States, Belgium and 5 more
- Volunteers
- 130 people
- Sponsor
- Incyte Corporation
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
The study is designed to be a randomized, open, multi-center, phase IIa/IIb seamless adaptive trial. Phase IIa: The study consists of a screening period, a core treatment period, an open label extension period, and a safety…
- Trial name
- NCT05232149
- Testing
- Orelabrutinib( lower dose), Orelabrutinib( higher dose)
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.